|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Linehan WM: Genetic basis of kidney
cancer: Role of genomics for the development of disease-based
therapeutics. Genome Res. 22:2089–2100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Porta C, Giglione P and Paglino C:
Targeted therapy for renal cell carcinoma: Focus on 2nd and 3rd
line. Expert Opin Pharmacother. 17:643–655. 2016. View Article : Google Scholar
|
|
4
|
Guttman M, Amit I, Garber M, French C, Lin
MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, et al:
Chromatin signature reveals over a thousand highly conserved large
non-coding RNAs in mammals. Nature. 458:223–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilusz JE, Sunwoo H and Spector DL: Long
noncoding RNAs: Functional surprises from the RNA world. Genes Dev.
23:1494–1504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fatica A and Bozzoni I: Long non-coding
RNAs: New players in cell differentiation and development. Nat Rev
Genet. 15:7–21. 2014. View
Article : Google Scholar
|
|
8
|
St Laurent G, Wahlestedt C and Kapranov P:
The Landscape of long noncoding RNA classification. Trends Genet.
31:239–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ntziachristos P, Abdel-Wahab O and
Aifantis I: Emerging concepts of epigenetic dysregulation in
hematological malignancies. Nat Immunol. 17:1016–1024. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ong CT and Corces VG: Enhancer function:
New insights into the regulation of tissue-specific gene
expression. Nat Rev Genet. 12:283–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie H, Zhu D, Xu C, Zhu H, Chen P, Li H,
Liu X, Xia Y and Tang W: Long none coding RNA HOTTIP/HOXA13 act as
synergistic role by decreasing cell migration and proliferation in
Hirschsprung disease. Biochem Biophys Res Commun. 463:569–574.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lian Y, Cai Z, Gong H, Xue S, Wu D and
Wang K: HOTTIP: A critical oncogenic long non-coding RNA in human
cancers. Mol Biosyst. 12:3247–3253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sang Y, Zhou F, Wang D, Bi X, Liu X, Hao
Z, Li Q and Zhang W: Up-regulation of long non-coding HOTTIP
functions as an oncogene by regulating HOXA13 in non-small cell
lung cancer. Am J Transl Res. 8:2022–2032. 2016.PubMed/NCBI
|
|
15
|
Wang SS, Wuputra K, Liu CJ, Lin YC, Chen
YT, Chai CY, Lin CS, Kuo KK, Tsai MH, Wang SW, et al: Oncogenic
function of the homeobox A13-long noncoding RNA HOTTIP-insulin
growth factor-binding protein 3 axis in human gastric cancer.
Oncotarget. 7:36049–36064. 2016.PubMed/NCBI
|
|
16
|
Ren YK, Xiao Y, Wan XB, Zhao YZ, Li J, Li
Y, Han GS, Chen XB, Zou QY, Wang GC, et al: Association of long
non-coding RNA HOTTIP with progression and prognosis in colorectal
cancer. Int J Clin Exp Pathol. 8:11458–11463. 2015.PubMed/NCBI
|
|
17
|
Zhang SR, Yang JK, Xie JK and Zhao LC:
Long noncoding RNA HOTTIP contributes to the progression of
prostate cancer by regulating HOXA13. Cell Mol Biol
(Noisy-le-grand). 62:84–88. 2016.
|
|
18
|
Cesana M, Cacchiarelli D, Legnini I,
Santini T, Sthandier O, Chinappi M, Tramontano A and Bozzoni I: A
long noncoding RNA controls muscle differentiation by functioning
as a competing endogenous RNA. Cell. 147:358–369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ergun S and Oztuzcu S: Oncocers:
ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways.
Tumour Biol. 36:3129–3136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
21
|
Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L
and Wang Z: Epigenetic silencing of miR-130b in ovarian cancer
promotes the development of multidrug resistance by targeting
colony-stimulating factor 1. Gynecol Oncol. 124:325–334. 2012.
View Article : Google Scholar
|
|
22
|
Wang Y, Zhang L, Zheng X, Zhong W, Tian X,
Yin B, Tian K and Zhang W: Long non-coding RNA LINC00161 sensitises
osteosarcoma cells to cisplatin-induced apoptosis by regulating the
miR-645-IFIT2 axis. Cancer Lett. 382:137–146. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He A, Liu Y, Chen Z, Li J, Chen M, Liu L,
Liao X, Lv Z, Zhan Y, Zhuang C, et al: Over-expression of long
noncoding RNA BANCR inhibits malignant phenotypes of human bladder
cancer. J Exp Clin Cancer Res. 35:1252016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma Y, Chen Y, Chen L, Liu Z, Ieong ML, Gao
F and Huang W: Promotion of Insulin-like growth factor II in cell
proliferation and epithelial-mesenchymal transition in
hepatocellular carcinoma. J Cancer Res Ther. 14:844–850. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kessler SM, Haybaeck J and Kiemer AK:
Insulin-like growth factor 2 - The oncogene and its accomplices.
Curr Pharm Des. 22:5948–5961. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer
A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J,
et al: An extensive microRNA-mediated network of RNA-RNA
interactions regulates established oncogenic pathways in
glioblastoma. Cell. 147:370–381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xie W, Yuan S, Sun Z and Li Y: Long
noncoding and circular RNAs in lung cancer: Advances and
perspectives. Epigenomics. 8:1275–1287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shukla S, Zhang X, Niknafs YS, Xiao L,
Mehra R, Cieślik M, Ross A, Schaeffer E, Malik B, Guo S, et al:
Identification and Validation of PCAT14 as Prognostic Biomarker in
Prostate Cancer. Neoplasia. 18:489–499. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Su H, Sun T, Wang H, Shi G, Zhang H, Sun F
and Ye D: Decreased TCL6 expression is associated with poor
prognosis in patients with clear cell renal cell carcinoma.
Oncotarget. 8:5789–5799. 2017.
|
|
30
|
Wu Y, Tan C, Weng WW, Deng Y, Zhang QY,
Yang XQ, Gan HL, Wang T, Zhang PP, Xu MD, et al: Long non-coding
RNA Linc00152 is a positive prognostic factor for and demonstrates
malignant biological behavior in clear cell renal cell carcinoma.
Am J Cancer Res. 6:285–299. 2016.PubMed/NCBI
|
|
31
|
Ellinger J, Alam J, Rothenburg J, Deng M,
Schmidt D, Syring I, Miersch H, Perner S and Müller SC: The long
non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients
with clear cell renal cell carcinoma. Am J Cancer Res. 5:2799–2807.
2015.PubMed/NCBI
|
|
32
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Nakajima K, Tabatabai ZL, Ishii N and Dahiya R: Long noncoding RNA
MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and
interacts with miR-205. Cancer Res. 75:1322–1331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ye H, Liu K and Qian K: Overexpression of
long noncoding RNA HOTTIP promotes tumor invasion and predicts poor
prognosis in gastric cancer. Onco Targets Ther. 9:2081–2088.
2016.PubMed/NCBI
|
|
34
|
Li F, Cao L, Hang D, Wang F and Wang Q:
Long non-coding RNA HOTTIP is up-regulated and associated with poor
prognosis in patients with osteosarcoma. Int J Clin Exp Pathol.
8:11414–11420. 2015.PubMed/NCBI
|
|
35
|
Chang S, Liu J, Guo S, He S, Qiu G, Lu J,
Wang J, Fan L, Zhao W and Che X: HOTTIP and HOXA13 are oncogenes
associated with gastric cancer progression. Oncol Rep.
35:3577–3585. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Z, Wang X, Liu R, Chen L, Yi J, Qi B,
Shuang Z, Liu M, Li X, Li S, et al: KDM4B-mediated epigenetic
silencing of miRNA-615-5p augments RAB24 to facilitate malignancy
of hepatoma cells. Oncotarget. 8:17712–17725. 2017.
|
|
37
|
Bai Y, Li J, Li J, Liu Y and Zhang B:
MiR-615 inhibited cell proliferation and cell cycle of human breast
cancer cells by suppressing of AKT2 expression. Int J Clin Exp Med.
8:3801–3808. 2015.PubMed/NCBI
|
|
38
|
Gao W, Gu Y, Li Z, Cai H, Peng Q, Tu M,
Kondo Y, Shinjo K, Zhu Y, Zhang J, et al: miR-615-5p is
epigenetically inactivated and functions as a tumor suppressor in
pancreatic ductal adenocarcinoma. Oncogene. 34:1629–1640. 2015.
View Article : Google Scholar
|
|
39
|
Heidegger I, Pircher A, Klocker H and
Massoner P: Targeting the insulin-like growth factor network in
cancer therapy. Cancer Biol Ther. 11:701–707. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rainier S, Johnson LA, Dobry CJ, Ping AJ,
Grundy PE and Feinberg AP: Relaxation of imprinted genes in human
cancer. Nature. 362:747–749. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen W, Feng Y, Zhao Q, Zhu Z and Dimitrov
DS: Human monoclonal antibodies targeting nonoverlapping epitopes
on insulin-like growth factor II as a novel type of candidate
cancer therapeutics. Mol Cancer Ther. 11:1400–1410. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ji Y, Wang Z, Li Z, Huang N, Chen H, Li B
and Hui B: Silencing IGF-II impairs C-myc and N-ras expressions of
SMMC-7721 cells via suppressing FAK/PI3K/Akt signaling pathway.
Cytokine. 90:44–53. 2017. View Article : Google Scholar
|
